Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors

1. 4.
   Corrected

   Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples · 2009

7 more references, whose wording the paper’s licence keeps private.

• The Role of p53 Signaling in Colorectal Cancer · 2021

• Clinical Overview of MDM2/X-Targeted Therapies · 2016

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.